Undisclosed Pipeline Programs

About Inventiva

Inventiva is a public biopharma company (Euronext: IVA) focused on discovering and developing oral small molecule therapies for significant unmet needs in fibrosis, lysosomal diseases, and oncology. Its core asset is lanifibranor, a unique pan-PPAR agonist in a pivotal global Phase 3 trial (NATiV3) for NASH/MASH, with topline results expected in H2 2026. The company's strategy is built on a robust discovery platform, a deep chemistry library, and key partnerships, positioning it as a potential leader in the evolving NASH treatment landscape.

Therapeutic Areas